uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
Show others and affiliations
2005 (English)In: Cancer Biotherapy and Radiopharmaceuticals, ISSN 1084-9785, E-ISSN 1557-8852, Vol. 20, no 3, 239-248 p.Article in journal (Refereed) Published
Abstract [en]

The 185 kDa transmembrane glycoprotein human epidermal growth factor receptor 2 (HER-2) (p185/neu, c-ErbB-2) is overexpressed in breast and ovarian cancers. Overexpression in breast cancer correlates with poor patient prognosis, and visualization of HER-2 expression might provide valuable diagnostic information influencing patient management. We have previously described the generation of a new type of affinity ligand, a 58-amino-acid affibody (Z(HER2:4)) with specific binding to HER-2. In order to benefit from avidity effects, we have created a bivalent form of the affibody ligand, (Z(HER2:4))2. The monovalent and bivalent ligands were compared in various assays. The new bivalent affibody has a molecular weight of 15.6 kDa and an apparent affinity (K(D)) against HER-2 of 3 nM. After radioiodination, using the linker molecule N-succinimidyl p-(trimethylstannyl) benzoate (SPMB), in vitro binding assays showed specific binding to HER-2 overexpressing cells. Internalization of 125I was shown after delivery with both the monovalent and the bivalent affibody. The cellular retention of 125I was longer after delivery with the bivalent affibody when compared to delivery with the monovalent affibody. With approximately the same affinity as the monoclonal antibody trastuzumab (Herceptin) but only one tenth of the size, this new bivalent molecule is a promising candidate for radionuclide-based detection of HER-2 expression in tumors. 125I was used in this study as a surrogate marker for the diagnostically relevant radioisotopes 123I for single photon emission computed tomography (SPECT)/gamma-camera imaging and 124I for positron emission tomography (PET).

Place, publisher, year, edition, pages
2005. Vol. 20, no 3, 239-248 p.
Keyword [en]
Amino Acid Sequence, Antibodies; Bispecific/*immunology, Biological Transport, Cell Line; Tumor, Humans, Iodine Radioisotopes, Kinetics, Ligands, Microscopy; Confocal, Molecular Sequence Data, Molecular Weight, Neoplasms/immunology/*metabolism/*radionuclide imaging, Receptor; erbB-2/chemistry/immunology/*metabolism, Research Support; Non-U.S. Gov't, Sequence Alignment
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-80490PubMedID: 15989469OAI: oai:DiVA.org:uu-80490DiVA: diva2:108404
Available from: 2007-02-12 Created: 2007-02-12 Last updated: 2010-06-07Bibliographically approved

Open Access in DiVA

No full text

Other links


Search in DiVA

By author/editor
Steffen, Ann-CharlottTolmachev, VladimirCarlsson, Jörgen
By organisation
Biomedical Radiation Sciences
In the same journal
Cancer Biotherapy and Radiopharmaceuticals
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 285 hits
ReferencesLink to record
Permanent link

Direct link